Table 2 Patient demographic and disease characteristics, by cohort

All N = 60

Bortezomib n = 20

Oxaliplatin n = 20

Taxane–Platinum n = 20

n (%)

n (%)

n (%)

n (%)

Women

46 (77%)

13 (65%)

13 (65%)

20 (100%)

White non-Hispanic

46 (77%)

14 (70%)

18 (90%)

14 (70%)

ECOG performance status < 2

57 (95%)

18 (90%)

20 (100%)

19 (95%)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Age, years

62.82 (10.53)

68.0 (8.25)

58.3 (7.68)

62.2 (12.94)